Naresh Doni Jayavelu
Overview
Explore the profile of Naresh Doni Jayavelu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
352
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayavelu N, Samaha H, Wimalasena S, Hoch A, Gygi J, Gabernet G, et al.
medRxiv
. 2025 Feb;
PMID: 39990570
The post-acute sequelae of SARS-CoV-2 (PASC), also known as long COVID, remain a significant health issue that is incompletely understood. Predicting which acutely infected individuals will go on to develop...
2.
Gabernet G, Maciuch J, Gygi J, Moore J, Hoch A, Syphurs C, et al.
bioRxiv
. 2025 Feb;
PMID: 39990442
Following SARS-CoV-2 infection, ~10-35% of COVID-19 patients experience long COVID (LC), in which often debilitating symptoms persist for at least three months. Elucidating the biologic underpinnings of LC could identify...
3.
Pickering H, Schaenman J, Phan H, Maguire C, Tsitsiklis A, Rouphael N, et al.
Nat Commun
. 2025 Jan;
16(1):586.
PMID: 39794319
Coronavirus disease 2019 (COVID-19) poses significant risks for solid organ transplant recipients, who have atypical but poorly characterized immune responses to infection. We aim to understand the host immunologic and...
4.
Wang K, Nie Y, Maguire C, Syphurs C, Sheen H, Karoly M, et al.
bioRxiv
. 2024 Dec;
PMID: 39651165
Hospitalized COVID-19 patients exhibit diverse immune responses during acute infection, which are associated with a wide range of clinical outcomes. However, understanding these immune heterogeneities and their links to various...
5.
Mishra A, Jajodia A, Weston E, Jayavelu N, Garcia M, Hossack D, et al.
Front Immunol
. 2024 Jul;
15:1387253.
PMID: 38947339
Type I diabetes is an autoimmune disease mediated by T-cell destruction of β cells in pancreatic islets. Currently, there is no known cure, and treatment consists of daily insulin injections....
6.
Gygi J, Maguire C, Patel R, Shinde P, Konstorum A, Shannon C, et al.
J Clin Invest
. 2024 May;
134(9).
PMID: 38690733
BACKGROUNDPatients hospitalized for COVID-19 exhibit diverse clinical outcomes, with outcomes for some individuals diverging over time even though their initial disease severity appears similar to that of other patients. A...
7.
Phan H, Tsitsiklis A, Maguire C, Haddad E, Becker P, Kim-Schulze S, et al.
Sci Transl Med
. 2024 Apr;
16(743):eadj5154.
PMID: 38630846
Age is a major risk factor for severe coronavirus disease 2019 (COVID-19), yet the mechanisms behind this relationship have remained incompletely understood. To address this, we evaluated the impact of...
8.
Phan H, Tsitsiklis A, Maguire C, Haddad E, Becker P, Kim-Schulze S, et al.
medRxiv
. 2024 Feb;
PMID: 38405760
Age is a major risk factor for severe coronavirus disease-2019 (COVID-19), yet the mechanisms responsible for this relationship have remained incompletely understood. To address this, we evaluated the impact of...
9.
Ozonoff A, Jayavelu N, Liu S, Melamed E, Milliren C, Qi J, et al.
Nat Commun
. 2024 Jan;
15(1):216.
PMID: 38172101
Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year...
10.
Gygi J, Maguire C, Patel R, Shinde P, Konstorum A, Shannon C, et al.
bioRxiv
. 2023 Nov;
PMID: 37986828
Hospitalized COVID-19 patients exhibit diverse clinical outcomes, with some individuals diverging over time even though their initial disease severity appears similar. A systematic evaluation of molecular and cellular profiles over...